Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Pierrette Lo"'
Autor:
Jeffrey W. Tyner, Brian J. Druker, Shannon K. McWeeney, Beth Wilmot, Daniel Bottomly, Pierrette Lo, Stephen E. Kurtz, Andrea Local, Nasrin Rastgoo, Hongying Zhang, Stephen B. Howell, William G. Rice
Supplementary Table from Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a397862d7233705acf11f41803a0be4
https://doi.org/10.1158/1535-7163.22523650.v1
https://doi.org/10.1158/1535-7163.22523650.v1
Autor:
Jeffrey W. Tyner, Brian J. Druker, Shannon K. McWeeney, Beth Wilmot, Daniel Bottomly, Pierrette Lo, Stephen E. Kurtz, Andrea Local, Nasrin Rastgoo, Hongying Zhang, Stephen B. Howell, William G. Rice
Supplementary Figure from Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ce2abc023cbee9a14e0599e6113119f
https://doi.org/10.1158/1535-7163.22523653.v1
https://doi.org/10.1158/1535-7163.22523653.v1
Autor:
William G. Rice, Stephen B. Howell, Hongying Zhang, Nasrin Rastgoo, Andrea Local, Stephen E. Kurtz, Pierrette Lo, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Brian J. Druker, Jeffrey W. Tyner
Publikováno v:
Molecular cancer therapeutics, vol 21, iss 7
Mol Cancer Ther
Mol Cancer Ther
Luxeptinib (CG-806) simultaneously targets FLT3 and select other kinase pathways operative in myeloid malignancies. We investigated the range of kinases it inhibits, its cytotoxicity landscape ex vivo with acute myeloid leukemia (AML) patient samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc9e1b4488dda808b39d791155511070
https://escholarship.org/uc/item/31f6q0nd
https://escholarship.org/uc/item/31f6q0nd
Autor:
Ted Laderas, Pierrette Lo, Shannon K. McWeeney, Yoko Kosaka, Guang Fan, Clare Lefave, Adam J. Lamble, Cristina E. Tognon, Lauren K. Brady, Marc M. Loriaux, Allie Maffit, Jennifer N. Saultz, Andy Kaempf, David Soong, Motomi Mori, Weiwei Wang, Homer Adams, Nicola Long, Fei Huang, Brian J. Druker, Evan F. Lind, Jeffrey W. Tyner
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with a 5-y survival of 29%. Immunotherapy is based on the premise that tumors suppress the immune system. We investigated the status of T cell immunity in AML at t
Autor:
Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E. Kurtz, Cristina E. Tognon, Kara Johnson, Melissa Abel, Anupriya Agarwal, Sammantha Avaylan, Erik Benton, Aurora Blucher, Uma Borate, Theodore Braun, Jordana Brown, Jade Bryant, Russell Burke, Amy Carlos, Bill H. Chang, Hyun Jun Cho, Stephen Christy, Cody Coblentz, Aaron M. Cohen, Amanda d’Almeida, Rachel Cook, Alexey Danilov, Kim-Hien T. Dao, Michie Degnin, James Dibb, Christopher A. Eide, Isabel A. English, Stuart Hagler, Heath Harrelson, Rachel Henson, Hibery Ho, Sunil Joshi, Brian Junio, Andy Kaempf, Yoko Kosaka, Ted Laderas, Matt Lawhead, Hyunjung Lee, Jessica T. Leonard, Chenwei Lin, Evan F. Lind, Selina Qiuying Liu, Pierrette Lo, Marc M. Loriaux, Samuel Luty, Julia E. Maxson, Tara Macey, Jacqueline Martinez, Jessica Minnier, Andrea Monteblanco, Motomi Mori, Quinlan Morrow, Dylan Nelson, Justin Ramsdill, Angela Rofelty, Alexandra Rogers, Peter Ryabinin, Jennifer N. Saultz, David A. Sampson, Samantha L. Savage, Robert Schuff, Robert Searles, Rebecca L. Smith, Stephen E. Spurgeon, Tyler Sweeney, Ronan T. Swords, Aashis Thapa, Karina Thiel-Klare, Elie Traer, Jake Wagner, Beth Wilmot, Joelle Wolf, Guanming Wu, Amy Yates, Haijiao Zhang, Christopher Cogle, Robert H. Collins, Michael W. Deininger, Christopher S. Hourigan, Craig T. Jordan, Tara L. Lin, Micaela E. Martinez, Rachel R. Pallapati, Daniel Pollyea, Tony Pomicter, Justin M. Watts, Scott Weir, Brian J. Druker, Shannon K. McWeeney, Jeffrey W. Tyner
Publikováno v:
SSRN Electronic Journal.
Autor:
Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E. Kurtz, Cristina E. Tognon, Kara Johnson, Melissa Abel, Anupriya Agarwal, Sammantha Avaylon, Erik Benton, Aurora Blucher, Uma Borate, Theodore P. Braun, Jordana Brown, Jade Bryant, Russell Burke, Amy Carlos, Bill H. Chang, Hyun Jun Cho, Stephen Christy, Cody Coblentz, Aaron M. Cohen, Amanda d’Almeida, Rachel Cook, Alexey Danilov, Kim-Hien T. Dao, Michie Degnin, James Dibb, Christopher A. Eide, Isabel English, Stuart Hagler, Heath Harrelson, Rachel Henson, Hibery Ho, Sunil K. Joshi, Brian Junio, Andy Kaempf, Yoko Kosaka, Ted Laderas, Matt Lawhead, Hyunjung Lee, Jessica T. Leonard, Chenwei Lin, Evan F. Lind, Selina Qiuying Liu, Pierrette Lo, Marc M. Loriaux, Samuel Luty, Julia E. Maxson, Tara Macey, Jacqueline Martinez, Jessica Minnier, Andrea Monteblanco, Motomi Mori, Quinlan Morrow, Dylan Nelson, Justin Ramsdill, Angela Rofelty, Alexandra Rogers, Kyle A. Romine, Peter Ryabinin, Jennifer N. Saultz, David A. Sampson, Samantha L. Savage, Robert Schuff, Robert Searles, Rebecca L. Smith, Stephen E. Spurgeon, Tyler Sweeney, Ronan T. Swords, Aashis Thapa, Karina Thiel-Klare, Elie Traer, Jake Wagner, Beth Wilmot, Joelle Wolf, Guanming Wu, Amy Yates, Haijiao Zhang, Christopher R. Cogle, Robert H. Collins, Michael W. Deininger, Christopher S. Hourigan, Craig T. Jordan, Tara L. Lin, Micaela E. Martinez, Rachel R. Pallapati, Daniel A. Pollyea, Anthony D. Pomicter, Justin M. Watts, Scott J. Weir, Brian J. Druker, Shannon K. McWeeney, Jeffrey W. Tyner
Publikováno v:
Cancer Cell. 40:850-864.e9
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and clinical annotations for a large cohort of AML patients, which facil
Autor:
Robert H. Collins, Deirdre Devine, Beth Wilmot, Justin Ramsdill, Erik Segerdell, Bruno C. Medeiros, Brian J. Druker, Dylan Nelson, Micaela E. Martinez, Ryan C. Johnson, Robert Schuff, Robert P. Searles, Scott Weir, James Dibb, Elie Traer, Pierrette Lo, Haijiao Zhang, Rachel Henson, Tara A. Macey, Isabel English, Cody Coblentz, Christopher A. Eide, Ceilidh Nichols, Aurora Blucher, Ryan M. Winters, David L. Wiest, Corinne Visser, Michael W. Deininger, Stephen E. Kurtz, Daniel A. Pollyea, Justin M. Watts, Amy S. Carlos, Denise C. Connolly, Andy Kaempf, Angela Rofelty, Samuel B. Luty, Rachel J. Cook, Jill Peters, Kristen Werth, Shannon K. McWeeney, Joseph Carroll, Samantha L. Savage, Ronan T. Swords, Uma Borate, Aashis Thapa, Abdusebur Jemal, Joelle Wolf, Patricia Kropf, Rebecca Smith, Tyler Sweeney, Russell T. Burke, Rachel R. Pallapati, Anna Reister Schultz, Kim Hien T. Dao, Daniel Bottomly, Cristina E. Tognon, Alexey V. Danilov, Jason M. Glover, Jason D. MacManiman, Michie Degnin, Amy Yates, Libbey White, David K. Edwards, Anupriya Agarwal, Christopher R. Cogle, Kevin Watanabe-Smith, Leylah Drusbosky, Nicola Long, Motomi Mori, Christopher S. Hourigan, Tara L. Lin, Chenwei Lin, Jacqueline Martinez, Bill H. Chang, Richie Carpenter, Stephen E. Spurgeon, Brian Junio, Marc M. Loriaux, Craig T. Jordan, Hibery Ho, Selina Qiuying Liu, Melissa L. Abel, Amanda d’Almeida, Jake Wagner, Jade Bryant, Jeffrey W. Tyner, Jessica Leonard, Kara Johnson
Publikováno v:
Nature
The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Here we repo
Autor:
Pierrette Lo, Cristina E. Tognon, Uma Borate, Stephen E. Spurgeon, Jeffrey W. Tyner, Brianna A. Norris
Publikováno v:
American Journal of Hematology. 92:E64-E66
Publikováno v:
Neurogastroenterology and Motility. 13:599-603
Lipopolysaccharide (LPS)-induced intestinalendotoxaemia perturbs motility and causes activationandinfluxofinflammatorycellsintothemuscletissue.Because rat submandibular gland peptide T (SGP-T;Thr-Asp-Ile-Phe-Glu-Gly-Gly), its carboxyl-terminalfragm
Autor:
Taher Abbasi, Robinson Vidva, Shahabuddin Usmani, Pierrette Lo, Leylah Drusbosky, Neeraj Kumar Singh, Cristina E. Tognon, Christopher R. Cogle, Brian J. Druker, S. Radhakrishnan, Deepak Parashar, Shireen Vali, Jeffrey W. Tyner
Publikováno v:
Blood. 128:1713-1713
Background: Data from a small clinical trial of venetoclax in acute myeloid leukemia (AML) recently supported FDA breakthrough therapy designation for use in combination with hypomethylating agents in treatment-naïve patients who are ineligible for